Navigation Links
Unigene to Present at TIDES 2012

BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV.

TIDES 2012 is the premier conference focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the applications and alternate delivery routes of peptide therapeutics.

Target Peptide Optimization and Recombinant Manufacturing of an Orally Delivered Peptide for the Treatment of Obesity

Spotlight Presentation – Emerging Technologies Showcase – Peptides

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, May 22, 2012 at 4:30 p.m. PDT
  • Focus: Development and oral delivery of a potent lead compound for the treatment of obesity  using Unigene's Peptelligence™ technology

Alternative Delivery Platforms for Oligonucleotide and Peptide Therapeutics

Strategy Discussion Forum

  • Panelist: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Wednesday, May 23 at 4:00 p.m. PDT
  • Focus: The advantages/disadvantages of alternative delivery platforms for oligonucleotide and peptide therapeutics and their acceptability to physicians, patients and health providers

"TIDES 2012 is an ideal forum for showcasing advancements in peptide therapeutics, including Unigene's oral peptide delivery technology which we have branded as Peptelligence™," said Dr. Mehta. "Without question, the oral delivery of peptide therapeutics is the most significant recent advancement in the peptide space as it offers the opportunity to redefine the treatment regimen and increase the market potential for numerous debilitating, chronic conditions.  Unigene is at the forefront of this paradigm shift, making TIDES 2012 an extremely valuable scientific and business development event for building awareness among companies and institutions that are developing next-generation peptide compounds and looking for new ways to expand existing peptide franchises."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020 /

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
2. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
3. Unigene Reports Third Quarter 2011 Financial Results
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
7. Unigene Provides 2012 Business Outlook
8. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
9. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
10. Unigene to Present at IBCs 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
11. Unigene Appoints David Moskowitz as Chief Financial Officer
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Teledyne DALSA , a ... sensing technology, will introduce its CMOS X-Ray detector for ... November 29 to December 3, at McCormick Place in ... for diagnostic and interventional imaging will be on display in ... of advanced CMOS X-Ray detectors is the industry benchmark ...
(Date:11/24/2015)... Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen protection ... and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... A ...
(Date:11/24/2015)... 2015  BioPlast Manufacturing, a manufacturer of plastic ... diagnostic and biotech environments, announced today that it ... petri dishes. This acquisition is aligned with BioPlast ... products that are designed and tested by scientists ... Bristol, Pennsylvania ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Brillouin Energy Corp. Congress and Government officials ... renewable energy technologies capable of producing commercially useful amounts of thermal energy (heat) ... and HHT™ Boiler System reactor core modules were presented to Congress on Capitol ...
(Date:11/24/2015)... ... ... American Family Care (AFC), the nation’s leading provider of urgent care and ... Metro Atlanta’s North Point Mall. The clinic is designed to test the concept of ... to operate through Dec. 24. , Holiday Pop-Up Clinic , Official Opening November 27, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals ... and cost of health care services available to its members to help them ...
(Date:11/24/2015)... ... 24, 2015 , ... Bibliomotion is thrilled to announce the launch ... and Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford ... address the needs of patients and their families, shaped my desire to improve the ...
(Date:11/24/2015)... ... ... Robert Yeager CEO of PharmMD, has announced the release of ... been multiple breakthroughs and challenges as healthcare reform moves out of its infancy and ... partners to stay ahead of the curve by breaking down barriers for every patient, ...
Breaking Medicine News(10 mins):